Analysts Set Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Target Price at $57.57

Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETAGet Rating) have received a consensus rating of “Hold” from the eight brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $57.57.

Several analysts have recently issued reports on RETA shares. Citigroup increased their target price on Reata Pharmaceuticals from $43.00 to $46.00 and gave the stock a “buy” rating in a report on Friday, May 27th. Robert W. Baird reduced their price objective on Reata Pharmaceuticals from $37.00 to $27.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 9th. Finally, The Goldman Sachs Group reduced their price objective on Reata Pharmaceuticals from $93.00 to $73.00 and set a “buy” rating on the stock in a research note on Tuesday, May 24th.

Reata Pharmaceuticals Stock Performance

RETA opened at $26.50 on Thursday. The firm has a market cap of $967.25 million, a P/E ratio of -3.17 and a beta of 1.16. Reata Pharmaceuticals has a 52-week low of $18.47 and a 52-week high of $114.80. The business’s fifty day moving average is $28.21 and its 200-day moving average is $30.00.

Reata Pharmaceuticals (NASDAQ:RETAGet Rating) last released its earnings results on Monday, August 8th. The company reported ($2.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.90) by ($0.12). The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $1.46 million. Reata Pharmaceuticals had a negative return on equity of 190.87% and a negative net margin of 3,045.98%. The business’s revenue for the quarter was down 65.7% compared to the same quarter last year. During the same period last year, the company posted ($2.00) earnings per share. On average, research analysts predict that Reata Pharmaceuticals will post -8.37 earnings per share for the current fiscal year.

Institutional Trading of Reata Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. US Bancorp DE raised its position in shares of Reata Pharmaceuticals by 930.5% during the first quarter. US Bancorp DE now owns 1,824 shares of the company’s stock worth $60,000 after acquiring an additional 1,647 shares during the last quarter. UBS Group AG raised its position in shares of Reata Pharmaceuticals by 42.2% during the second quarter. UBS Group AG now owns 2,558 shares of the company’s stock worth $78,000 after acquiring an additional 759 shares during the last quarter. Macquarie Group Ltd. raised its position in shares of Reata Pharmaceuticals by 51.1% during the second quarter. Macquarie Group Ltd. now owns 2,768 shares of the company’s stock worth $84,000 after acquiring an additional 936 shares during the last quarter. Amalgamated Bank bought a new stake in Reata Pharmaceuticals in the first quarter worth approximately $141,000. Finally, Virtus ETF Advisers LLC increased its holdings in Reata Pharmaceuticals by 282.5% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,684 shares of the company’s stock worth $150,000 after purchasing an additional 4,198 shares in the last quarter. 76.00% of the stock is owned by institutional investors and hedge funds.

Reata Pharmaceuticals Company Profile

(Get Rating)

Reata Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.

Recommended Stories

Analyst Recommendations for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.